Centene Corporation CNC
Composite 54/100; the shares have moved about 50% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 22/100 — a strong mark against it.
Momentum ranks 85/100 — a strong point in its favour. Valuation ranks 81/100 — a strong point in its favour. Balance-sheet strength ranks 60/100 — a slight point in its favour.
Quality ranks 22/100 — a strong mark against it. Growth ranks 36/100 — a moderate mark against it.
What the company does Centene Corporation (CNC) is a managed care company serving under-insured families and commercial organizations in the U.S. through Medicaid, Medicare, Commercial, and Other segments. It provides health insurance programs, including Medicaid expansion, Medicare supplement plans, and healthcare marketplace products.
Key financials Centene’s trailing ROE is -20.4%, ROA 2.5%, and ROCE -9.4%. Revenue growth is 19.4%, but EPS fell -316.2%. Margins show gross 11.4%, operating 3.8%, and net -2.8%. Debt/Equity is 0.71, with a current ratio of 1.15 and FCF yield of 29.0%.
Stock health Sideravia scores Quality 21.6 and Growth 35.8, but Valuation 80.6 and Momentum 85.2. Piotroski F-Score is 7/9, Altman Z is 2.77. The stock is up 127.35% over 12 months, with RSI(14) at 57.70.
Price vs fair value CNC trades at a **discount of 6.40%** to the analyst mean target of 71.67. - Recent leadership change (new CIO) signals operational focus (2026-09-03). - Healthcare inflation may support growth for peers including CNC (2026-09-03). - Membership growth highlighted, but profitability remains a key concern (2026-09-02). - Stock surged 117% in a year, prompting valuation scrutiny (2026-09-02).
Looking forward Forward P/E is 13.21 and EV/EBITDA is 3.91, reflecting a low valuation multiple. Momentum remains strong, but weak profitability and high leverage warrant caution. Analysts debate fair value amid operational turnaround efforts.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.